United States was Phibro Animal Health’s largest region in fiscal 2026, bringing in $877.13M of $1.52B (58%).
| Geography | FY 2012 | FY 2013 | FY 2014 | FY 2015 | FY 2016 | FY 2017 | FY 2018 | FY 2019 | FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | FY 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| United States | $578.77M | $584.76M | $739.92M | $877.13M | |||||||||||
| Us | — | — | — | — | |||||||||||
| Latin America & Canada | $219.85M | $247.71M | $298.65M | $340.67M | |||||||||||
| Europe, Middle East & Africa | $117.82M | $121.98M | $160.23M | $187.94M | |||||||||||
| Europe Middle East & Africa | — | — | — | — | |||||||||||
| Il | — | — | — | — | |||||||||||
| Asia Pacific | $61.46M | $63.23M | $97.42M | $112.36M | |||||||||||
| Europe & Africa | — | — | — | — | |||||||||||
| Total | $977.89M | $1.02B | $1.30B | $1.52B |
Phibro Animal Health brought in $1.52B from its four regions in fiscal 2026, the year ended June 30, 2026. That was up 17.1% from $1.30B in fiscal 2025. United States was the largest at $877.13M (57.8%), ahead of Latin America & Canada at $340.67M (22.4%) and Europe, Middle East & Africa at $187.94M (12.4%). The remaining region, Asia Pacific, brought in $112.36M.
Compared with fiscal 2025, United States grew fastest, up 18.5% to $877.13M. Every region above 2% of revenue grew. From fiscal 2023 to 2026, combined revenue from these regions grew from $977.89M to $1.52B, a compound annual growth rate of 15.8%. United States' share of the total fell from 59.2% to 57.8%.
Mfas & Other was Phibro Animal Health’s largest product and service line in fiscal 2026, bringing in $810.73M of $1.52B (53%).
| Product and Service | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | FY 2026 |
|---|---|---|---|---|---|---|
| Mfas & Other | $387.35M | $420.96M | $646.35M | $810.73M | ||
| Mineral Nutrition | $242.66M | $243.66M | $253.24M | $282.34M | ||
| Nutritional Specialties | $172.50M | $164.67M | $179.29M | $195.07M | ||
| Vaccines | $100.00M | $120.85M | $137.15M | $156.42M | ||
| Performance Products | $75.38M | $67.53M | $80.18M | $73.53M | ||
| Total | $977.89M | $1.02B | $1.30B | $1.52B |
Phibro Animal Health brought in $1.52B from its five product and service lines in fiscal 2026, the year ended June 30, 2026. That was up 17.1% from $1.30B in fiscal 2025. Mfas & Other was the largest at $810.73M (53.4%), ahead of Mineral Nutrition at $282.34M (18.6%) and Nutritional Specialties at $195.07M (12.8%). The other two lines brought in $229.95M combined.
Compared with fiscal 2025, Mfas & Other grew fastest, up 25.4% to $810.73M, while Performance Products fell the most, down 8.3% to $73.53M. From fiscal 2023 to 2026, combined revenue from these lines grew from $977.89M to $1.52B, a compound annual growth rate of 15.8%. Mfas & Other's share of the total rose from 39.6% to 53.4%.
Animal Health was Phibro Animal Health’s largest segment in fiscal 2026, bringing in $1.16B of $1.52B (77%).
| Segment | FY 2012 | FY 2013 | FY 2014 | FY 2015 | FY 2016 | FY 2017 | FY 2018 | FY 2019 | FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | FY 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Animal Health | $659.85M | $706.48M | $962.80M | $1.16B | |||||||||||
| Mineral Nutrition | $242.66M | $243.66M | $253.24M | $282.34M | |||||||||||
| Performance Products | $75.38M | $67.53M | $80.18M | $73.53M | |||||||||||
| Total | $977.89M | $1.02B | $1.30B | $1.52B |
Phibro Animal Health brought in $1.52B from its three segments in fiscal 2026, the year ended June 30, 2026. That was up 17.1% from $1.30B in fiscal 2025. Animal Health was the largest at $1.16B (76.6%), ahead of Mineral Nutrition at $282.34M (18.6%) and Performance Products at $73.53M (4.8%).
Compared with fiscal 2025, Animal Health grew fastest, up 20.7% to $1.16B, while Performance Products fell the most, down 8.3% to $73.53M. From fiscal 2023 to 2026, combined revenue from these segments grew from $977.89M to $1.52B, a compound annual growth rate of 15.8%. Animal Health's share of the total rose from 67.5% to 76.6%.
Phibro Animal Health (PAHC) reports its revenue by geography, by product and service and by segment. In fiscal 2026, United States was its largest region, bringing in $877.13M (57.8% of the total), followed by Latin America & Canada at $340.67M (22.4%).
United States was Phibro Animal Health's largest region in fiscal 2026, bringing in $877.13M, or 57.8% of the $1.52B total across its four regions.
Mfas & Other was Phibro Animal Health's largest product and service line in fiscal 2026, bringing in $810.73M, or 53.4% of the $1.52B total across its five product and service lines.
Animal Health was Phibro Animal Health's largest segment in fiscal 2026, bringing in $1.16B, or 76.6% of the $1.52B total across its three segments.
Among Phibro Animal Health's regions that make up at least 2% of revenue, United States grew fastest in fiscal 2026, up 18.5% from $739.92M to $877.13M.
Every figure comes from Phibro Animal Health's annual financial filings, as reported. Each line keeps the name Phibro Animal Health gives it, and years follow its fiscal calendar.
Phibro Animal Health's revenue by geography goes back to fiscal 2012, with figures through fiscal 2026. The latest four fiscal years are free to view, and the full history is available with a Business Quant subscription.